



## Original Article

# Comparison of Nonacral Cutaneous Lentiginous Melanomas According to the Degree of Solar Elastosis: Support for the New World Health Organization Classification



R. Moro <sup>a,b,c</sup>, F. Mayo-Martínez <sup>b</sup>, Z. García-Casado <sup>d</sup>, M. Aguerralde-Martin <sup>e</sup>, Victor Traves <sup>f</sup>, E. Manrique-Silva <sup>b</sup>, C. Requena <sup>b</sup>, D.E. Elder <sup>g</sup>, E. Nagore <sup>b,h,\*</sup>

<sup>a</sup> Escuela de Doctorado, Universidad Católica de Valencia San Vicente Mártir, Valencia, Spain

<sup>b</sup> Departamento de Dermatología, Instituto Valenciano de Oncología, Valencia, Spain

<sup>c</sup> Instituto Dermatológico Tekderma, Hospital Vithas Valencia 9 de Octubre, Valencia, Spain

<sup>d</sup> Laboratorio de Biología Molecular, Instituto Valenciano de Oncología, Valencia, Spain

<sup>e</sup> Departamento de Estadística e Investigación Operativa Aplicadas y de Calidad, Universitat Politècnica de València, Valencia, Spain

<sup>f</sup> Departamento de Anatomía Patológica, Instituto Valenciano de Oncología, Valencia, Spain

<sup>g</sup> Hospital de la Universidad de Pensilvania, Filadelfia, PA, United States

<sup>h</sup> Facultad de Medicina, Universidad Católica de Valencia San Vicente Mártir, Valencia, Spain

## ARTICLE INFO

## Keywords:

Melanoma

Lentiginous melanoma

Solar elastosis

Oncology

Chronic sun damage

WHO classification

## ABSTRACT

**Background and aims:** The new WHO classification distinguishes two main pathogenic pathways for cutaneous melanoma, low and high-chronic sun damage (CSD). However, there are no studies to support its validity in the category of non-acral cutaneous lentiginous melanoma (NACLm). Thus, the aim of this study was to correlate the degree of solar elastosis (SE) with a range of clinicopathologic and genomic parameters in a cohort of NACLms.

**Material and methods:** We conducted a retrospective cohort study of patients affected by an in situ or invasive NACLm distributed across three groups depending on the grade of SE. NACLm includes lentigo maligna melanoma and lentigo maligna, and other non-acral cutaneous lesions with a lentiginous growth pattern.

**Results:** The study included a total of 257 patients, 132 men (51.4%) and 125 women (48.6%) with a median age of 71 years. SE grade I was reported in 38 cases (14.8%), grade II in 61 cases (23.7%), and grade III in 158 cases (61.5%). Higher SE grade was related to head/neck location, older age at diagnosis and presence of lentiginous in melanoma area. Lower SE grade was related to other locations, higher nevi count, presence of regression and BRAF V600E mutation (univariate logistic regression quantification: V600E vs WT; OR, 0.23; 95%CI, 0.05–1.06;  $p = 0.059$ ).

**Conclusion:** SE grade is useful to classify NACLms in different groups distinguished by their clinical, pathological, and molecular features. These results endorse the new WHO classification of low- and high-CSD melanomas. Moreover, they highlight the importance of reporting the grade of SE in the pathological report.

## Introduction

The 4th edition of the World Health Organization (WHO) Classification of Skin Tumors, published in 2018, reclassified superficial spreading melanomas (SSMs) as low-CSD melanomas and lentigo maligna melanomas (LMMs) as high-CSD melanomas.<sup>1,2</sup> High-CSD is defined by the histological observation of severe (grade III) solar elastosis (SE) in the dermis of the surrounding healthy skin around the cutaneous melanoma (CM).<sup>1–3</sup> Grade III SE is described by the pres-

ence of homogeneous clumps of elastotic material that have lost their texture of individual fibrils<sup>2</sup> (Fig. 1A). In turn, low-CSD is the absence of SE, or the presence of mild (grade I [Fig. 1B]) or moderate (grade II) SE. Thus, the grade of SE became a major criterion to distinguish between these two types of CM.

Non-acral cutaneous lentiginous melanomas (NACLms) are mostly represented by LMM and its precursor lentigo maligna (LM). According to the new WHO classification, these CMs that present a lentiginous growth pattern must demonstrate a grade III SE to be defined as high-CSD melanomas/LMMs.<sup>2</sup> However, low-CSD melanomas/SSMs can occasionally occur in high-CSD skin. Moreover, moderate-to-severe SE

\* Corresponding author.

E-mail address: [enagore@fivo.org](mailto:enagore@fivo.org) (E. Nagore).

<https://doi.org/10.1016/j.ad.2025.104519>

Received 24 November 2024; Accepted 16 February 2025

Available online 4 December 2025

0001-7310/© 2025 AEDV. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).




Fig. 1. Histological examples of non-acral cutaneous lentiginous melanomas with grade III solar elastosis (A) and grade I solar elastosis (B).

can be sometimes considered sufficient to define high-CSD.<sup>2</sup> Finally, SE is not always reported in pathological reports.

On the other hand, although the classical histological definition of LMM includes the presence of SE in the dermis, it does not provide a threshold.<sup>4</sup> Indeed, there are NACLMS with grade I SE or without SE. These lesions are usually categorized as lentiginous melanomas.<sup>5</sup> According to the WHO classification, these lesions should be categorized as lentiginous low-CSD melanomas/SSMs.<sup>6</sup>

The new WHO classification is supported by molecular findings that distinguish the various melanoma pathways. The most common driver mutation of low-CSD melanomas/SSMs is *BRAF* V600E, while the driver mutations of high-CSD melanomas/LMMs include *NF1*, *BRAF* V600K (or other non-V600E mutations), *NRAS* and *c-KIT*.<sup>1–3,6–8</sup> Nevertheless, these molecular differences have not been analyzed in the category of NACLMS.

Based on these findings, we conducted a retrospective study of patients with histologically confirmed NACLMS, stratified by the grade of solar elastosis reported in the pathology report, to identify clinical, pathological, and molecular differences among groups that may support the new WHO classification.

## Materials and methods

### Study design

The present study is a retrospective cohort study on patients affected by in situ or invasive NACLMS. Cases were collected from January 1st, 2000 through June 25th, 2021.

Table 1

Criteria used to define the three grades of solar elastosis.

Grade I	Absence of elastotic fibers, or the presence of rare elastotic fibers visible only at 200× magnification, or scattered elastotic fibers appearing as individual units.
Grade II	Densely scattered elastotic fibers primarily arranged in clusters rather than as individual units.
Grade III	Amorphous deposits of blue-gray material with lost fibrillary texture.

We aimed to correlate the degree of solar elastosis (SE) with a range of clinicopathologic and genomic parameters available in our database (including mutational status of *BRAF*, *NRAS*, *c-KIT*, and *pTERT*), as a test of the validity and applicability of the WHO classification in our setting. Therefore, we established a category of NACLMS in the computerized melanoma patient database of the Department of Dermatology of *Instituto Valenciano de Oncología* (Valencia, España). NACLMS generally correspond to the traditional categories of LM, LMM, and related entities. Other categories include nonacral cutaneous lesions with a lentiginous growth pattern that do not conform to the LM or LMM classifications, such as lentiginous melanomas.<sup>5</sup>

Therefore, acral lentiginous melanomas and mucosal lentiginous melanomas were excluded. All patients have their prior written informed consent for inclusion in the database and participation in the study. Cases lacking information on the grade of solar elastosis in the pathology report were also excluded (Fig. 2).

Grade of SE defined the three main study groups: (I) absent or mild SE (0, 0+, 1–, 1 and 1+); (II) moderate SE (2–, 2 and 2+); and (III) severe SE (3–, 3 and 3+). This grouping used the 11 grades of SE (from 0 to 3+) depicted in the WHO manual and in a previous work by the same authors.<sup>1,7</sup>

During the statistical analysis, two more groups were defined by CSD status: (1) low-CSD (from 0 to 2–) and (2) high-CSD (from 2 to 3+). Previously, these two groups have been defined as non-CSD and CSD.<sup>7</sup> Table 1 illustrates the criteria used to define SE grade.

Variables selected were gender, age at diagnosis (<71 vs ≥71 years), history of sunburns at melanoma area, history of chronic solar exposure, presence of lentigines in melanoma area, history of actinic keratosis, history of basal/squamous cell carcinoma, nevi count (<20 vs ≥20 nevi), history of multiple melanoma, history of familial melanoma, location (1 = head/neck vs 2 = upper extremity vs 3 = trunk vs 4 = lower extremity), ulceration status, mitotic rate (0 vs ≥1 mitosis/mm<sup>2</sup>), histological regression status, Breslow thickness (in situ vs <2 mm vs ≥2 mm), *BRAF* status [WT (wild type) vs V600E vs non-V600E], *NRAS* status (WT vs mutated), *c-KIT* status (WT vs mutated), *pTERT* status (WT vs mutated), number of variants of *MC1R* (0 vs ≥1) and R variants (RHC) (0 vs ≥1). Somatic genetic analysis is described in the [supplementary data](#).


### Statistical analysis

Continuous variables were expressed as mean and standard deviation when they followed a normal distribution at Kolmogorov–Smirnov test; otherwise, they were expressed as median and interquartile range (IQR). Qualitative variables were expressed as number and percentage.

Contingency tables were used to assess differences in the distribution of each variable across the 3 study groups and the significance was analyzed by Pearson's chi-square and Fisher's exact tests.

Regression imputation was performed to complete the dataset. Variables relative to *BRAF*, *NRAS*, *c-KIT* and *pTERT* status, and no. of variants of *MC1R* were not imputed to avoid creating false imputations. Consequently, the missing values of these variables were labeled as unknown.

A principal component analysis (PCA) was performed as exploratory analysis. Individuals were plotted in these components depending on



**Fig. 2.** Consort diagram describing inclusions and exclusion criteria of the study. NACL M, non-acral cutaneous lentiginous melanoma; LMM, lentigo maligna melanoma; SSM, superficial spreading melanoma; CSD, cumulative sun damage.

their grade of SE, that was introduced as an external variable. The results of PCA were validated by residual sum of squares and T<sup>2</sup> of Hotelling methods.

The PCA was followed by a partial least squares (PLS) regression. In this case, grade of SE was introduced as the response variable, while the other variables were transformed to predict them in the model; continuous variables were centered and scaled, and the qualitative ones were converted in dummies. The PLS model was validated both for individuals (residual sum of squares and T<sup>2</sup> of Hotelling methods) and variables [analyzing the variable importance of projection (VIP) and coefficient of regression]. For each variable included in the final PLS model, a univariate ordinal logistic regression was performed to quantify its association with the response variable.

The same analysis was then conducted for the CSD. In this case, a PLS discriminant analysis (PLS-DA) was used to create the models instead of a PLS regression, since CSD cannot be treated as an ordinal variable.

Finally, data of the mutational status were not available in all patients. Thus, PLS and PLS-DA were repeated including only the patients that had data of *BRAF* and *NRAS* status.

Statistical analysis was performed using IBM SPSS version 20.0 and RStudio version 4.1.0. All *p* values were two-tailed, and statistical significance was set at  $\alpha = 0.05$ .

**Results**

A total of 359 patients with histological diagnosis of NACL M were recovered from the IVO Dermatology Department melanoma database. A total of 102 patients were excluded because SE grade was not available. Therefore, the final dataset included 257 patients (132 men [51.4%] and 125 women [48.6%]) with a median age of 71 years (IQR, 61–77).

SE grade I was observed in 38 cases (14.8%), grade II in 61 (23.7%), and grade III in 158 (61.5%) (Fig. 2). Contingency tables showed that SE grade III was statistically associated with age at diagnosis  $\geq 71$  years ( $p < 0.0001$ ), presence of lentigines in melanoma area ( $p < 0.0001$ ), nevi count  $< 20$  ( $p < 0.0001$ ), head/neck location ( $p < 0.0001$ ), and absence of histological regression ( $p < 0.0001$ ) (Table 2 ).

Before completing the dataset with regression imputation, a total of 8 cases were excluded because more than 30% of their data were missing. Thus, the dataset was restricted to 249 patients.

The PCA score plot for prediction of SE grade extracted seven principal components, which explained 52.4% of the variability. No clear spontaneous distribution of individuals was observed. The PLS final model explained 24.5% of the variability and 54.4% of the variability of SE grade. In the PLS score plot a clear difference between SE grade I and III was reported, while there was some confusion with the SE grade II, which aligns with either grade I or III. PLS weights showed that higher SE grade was related to head/neck location and, less so, to older age at diagnosis and presence of lentigines in melanoma area. On the other hand, lower SE grade was related to other locations and higher nevi count. Additionally, the presence of histological regression seemed to be related to a lower SE grade, but with a weak association (Fig. 3). Although *pTERT* and *BRAF* status were included in the PLS final model, their low VIPs and not significant *p*-values impaired evaluating their relation with SE grade. PLS results were quantified by univariate ordinal logistic regressions (Table 3 ). The classification error rate of this model was 36.7%.

The confusion matrix (the table layout that permits observation of the algorithm performance) showed that the main problem of this model was classifying patients with SE grade II: 9 of them were classified as SE grade I, and 24 as SE grade III. Although the CSD status was introduced in the PLS to explain the confusion, the score plot did not show a clear difference across the groups (Fig. 4). Instead, the analysis showed that among the 9 patients with SE grade II misclassified as grade I, 6 had low CSD and 3 had high CSD. In contrast, among the 24 patients predicted as grade III, only 4 had low CSD.

PLS-DA was realized using CSD status as the response variable. The final model explained 17.4% of the variability and 55.9% of CSD status variability. Although the error rate of this model was lower than the previous one (14.35%), it could not discriminate between low-CSD and high-CSD (Fig. 5).

Including only patients with available *BRAF* and *NRAS* mutation status restricted the dataset to 110 patients. PLS with SE grade as response variable produced a final model that explained 27.3% of the variability and 47.1% of SE grade variability. The PLS score and weights showed similar results to those obtained with the full dataset. In addition to those results, a weak association was observed between lower SE grade and *BRAF* V600E mutation, as well as between lower SE grade and the presence of regression. Even if gender and a past medical history of chronic solar exposure did not show relevant VIPs or significant *p*-

**Table 2**  
Population description, and contingency tables between elastosis grades and variables.

Variables	Elastosis			p
	Grade I	Grade II	Grade III	
<i>Gender</i>				0.278
Male	24 (63.2%)	31 (50.8%)	77 (48.7%)	
Female	14 (36.8%)	30 (49.2%)	81 (51.3%)	
<i>Age at diagnosis</i>				< 0.001
<71 years	29 (76.3%)	29 (47.5%)	64 (40.5%)	
≥71 years	9 (23.7%)	32 (52.5%)	94 (59.5%)	
<i>Sunburns in melanoma area (m.v. = 35)</i>				0.133
No	15 (44.1%)	13 (24.1%)	40 (29.9%)	
Yes	19 (55.9%)	41 (75.9%)	94 (70.1%)	
<i>Chronic solar exposure (m.v. = 26)</i>				0.088
No	26 (70.3%)	32 (59.3%)	71 (50.7%)	
Yes	11 (29.7%)	22 (40.7%)	69 (49.3%)	
<i>Lentiginos in melanoma area (m.v. = 23)</i>				< 0.001
No	11 (28.9%)	13 (23.6%)	10 (7.1%)	
Yes	27 (71.1%)	42 (76.4%)	131 (92.9%)	
<i>Actinic keratosis (m.v. = 23)</i>				0.056
No	30 (78.9%)	42 (73.7%)	85 (61.2%)	
Yes	8 (21.1%)	15 (26.3%)	54 (38.8%)	
<i>BCC/SCC (m.v. = 10)</i>				0.211
No	31 (81.6%)	41 (70.7%)	123 (81.5%)	
Yes	7 (18.4%)	17 (29.3%)	28 (18.5%)	
<i>Nevi count (m.v. = 37)</i>				< 0.001
<20 nevi	24 (64.9%)	41 (77.4%)	120 (92.3%)	
≥20 nevi	13 (35.1%)	12 (22.6%)	10 (7.7%)	
<i>Multiple melanoma</i>				0.072
No	33 (86.8%)	59 (96.7%)	151 (95.6%)	
Yes	5 (13.2%)	2 (3.3%)	7 (4.4%)	
<i>Familial melanoma (m.v. = 20)</i>				0.069
No	32 (84.2%)	52 (92.9%)	136 (95.1%)	
Yes	6 (15.8%)	4 (7.1%)	7 (4.9%)	
<i>Location (m.v. = 1)</i>				< 0.001
1 = head/neck	11 (28.9%)	36 (60.0%)	157 (99.4%)	
2 = upper extremity	6 (15.8%)	9 (15.0%)	1 (0.6%)	
3 = trunk	15 (39.5%)	9 (15.0%)	0 (0.0%)	
4 = lower extremity	6 (15.8%)	6 (10.0%)	0 (0.0%)	
<i>Ulceration</i>				0.393
No	37 (97.4%)	55 (90.2%)	147 (93.0%)	
Yes	1 (2.6%)	6 (9.8%)	11 (7.0%)	
<i>Mitotic rate (m.v. = 15)</i>				0.033
0 mitosis/mm <sup>2</sup>	35 (92.1%)	42 (71.2%)	119 (82.1%)	
≥1 mitosis/mm <sup>2</sup>	3 (7.9%)	17 (28.8%)	26 (17.9%)	
<i>Regression (m.v. = 33)</i>				< 0.001
No	28 (77.8%)	49 (86.0%)	129 (98.5%)	
Yes	8 (22.2%)	8 (14.0%)	2 (1.5%)	
<i>Breslow thickness</i>				0.046
In situ	24 (63.2%)	30 (49.2%)	98 (62.0%)	
< 2 mm	13 (34.2%)	27 (44.3%)	41 (25.9%)	
≥2 mm	1 (2.6%)	4 (6.6%)	19 (12.0%)	
<i>BRAF status (m.v. = 147)</i>				0.426
WT	12 (80.0%)	33 (86.8%)	53 (93.0%)	
V600E	2 (13.3%)	3 (7.9%)	1 (1.8%)	
Non-V600E	1 (6.7%)	2 (5.3%)	3 (5.3%)	
<i>NRAS status (m.v. = 146)</i>				0.731
WT	13 (86.7%)	32 (84.2%)	52 (89.7%)	
Mutated	2 (13.3%)	6 (15.8%)	6 (10.3%)	
<i>c-KIT status (m.v. = 172)</i>				0.992
WT	12 (92.3%)	28 (93.3%)	39 (92.9%)	
Mutated	1 (7.7%)	2 (6.7%)	3 (7.1%)	
<i>pTERT status (m.v. = 190)</i>				0.468
WT	8 (66.7%)	11 (45.8%)	15 (48.4%)	
Mutated	4 (33.3%)	13 (54.2%)	16 (51.6%)	
<i>MC1R variants (m.v. = 82)</i>				0.948
0	10 (34.5%)	18 (37.5%)	37 (37.8%)	
≥1	19 (65.5%)	30 (62.5%)	61 (62.2%)	
<i>RHC variants (m.v. = 83)</i>				0.433
0	23 (79.3%)	39 (81.2%)	70 (72.2%)	
≥1	6 (20.7%)	9 (18.8%)	27 (27.8%)	

m.v., missing values; BCC, basal cell carcinoma; SCC, squamous cell carcinoma; WT, wild type; RHC, R variants.




Fig. 3. Partial least squares regression weights by solar elastosis grade. WT, wild type; Unk, unknown; location 1, head/neck; 2, upper extremity; 3, trunk; 4, lower extremity.

values for the regression coefficients, they were left in the model to avoid increasing its error rate (Fig. 6). Univariate ordinal logistic regression quantified *BRAF* V600E (V600E vs WT: OR, 0.23; 95%CI, 0.05–1.06;  $p = 0.059$ ) and other variable association with SE grade (Table 4). The classification error rate of this model was 20.59%.

### Discussion

This observational retrospective study collected data on 257 NACLM patients. Most of them (61.5%) had grade III SE in the dermis surrounding the tumor (Fig. 2). This finding was statistically associated with head/neck location, older age, presence of lentiginos in melanoma area, having less than 20 nevi, and absence of histological regression (Table 2). Analyzing the full dataset of patients, mutational status of *BRAF*, *NRAS*, *c-KIT*, and *pTERT* were not statistically associated with the grade of SE (Fig. 3). However, after restricting the dataset to the 110 patients with data on *BRAF* and *NRAS* status, a weak association between *BRAF* V600E mutation and a lower grade of SE was observed in the PLS weights (Fig. 6). Their relation was quantified as an OR of 0.23 with an almost significant  $p$ -value (0.059) (Table 4). This result showed that the grade of SE may serve to distinguish different pathogenetic pathways between CMs with a lentiginous growth pattern, as pointed out by the new WHO classification for CMs in general.<sup>1</sup>

The main limitation of these results is the low prevalence of mutations of *BRAF* and the other genes in the study population. Indeed,


only 12 out of 110 patients had a mutation of *BRAF*, half of them in V600E and the other half in non-V600E position. Nevertheless, observing the numerical distribution of *BRAF* mutations, it is remarkable that *BRAF* WT was more common in tumors with SE grade III vs SE grade II and I (93% vs 86.8% vs 80%, respectively), whereas V600E mutation was symmetrically distributed (1.8% vs 7.9% vs 13.3%, respectively) (Table 2). Thus, NACLMs with absent or mild SE harbor the *BRAF* V600E mutation more frequently than those with moderate or severe SE. This is consistent with former published literature of CM and the new WHO classification.<sup>1,3,6,8,9</sup> The main problem of the full dataset PLS model was classifying patients with SE grade II. In fact, the PLS confusion matrix showed that 33 patients with SE grade II were wrongly classified: 9 as SE grade I and 24 as SE grade III. The PLS score plot incorporating CSD status showed that among the 9 cases predicted as SE grade I, 6 (66.6%) were low CSD, whereas only 4 (16.6%) of the 24 cases predicted as SE grade III were correctly classified (Fig. 4). Consequently, although the CSD status could have better classified NACLM patients, the statistical analysis using it as the response variable did not result in significant PLS-DA final models (Fig. 5), which may be due to the cut-off point used to discriminate between low- and high-CSD that was set at SE grade 2 (the 7th grade out of 11), as previously described.<sup>1,7</sup> On the other hand, it may suggest that low- and high-CSD are opposite poles of the same disease spectrum that varies by the grade of SE in the dermis around the CM; thus, it may be difficult to set a clear cut-off point.

**Table 3**

Univariate ordinal logistic regressions quantifying partial least squares regression results with solar elastosis grade as the response variable. Location 1, head/neck; 2, upper extremity; 3, trunk; 4, lower extremity.

Univariate analysis		Elastosis grade		
Ordinal logistic regression	#	OR (95%CI)	p	
<i>Location</i>				
1	198	Ref		
2	16	0.05 (0.02–0.14)	<0.001	
3	24	0.02 (0.007–0.05)	<0.001	
4	11	0.03 (0.007–0.09)	<0.001	
<i>Age</i>				
		1.04 (1.02–1.07)	<0.001	
<i>Presence of lentiginos in melanoma area</i>				
No	35	Ref		
Yes	214	3.73 (1.92–7.32)	<0.001	
<i>Regression</i>				
No	227	5.81 (2.66–13.06)	<0.001	
Yes	22	Ref		
<i>pTERT</i>				
WT	34	Ref		
Mut	33	1.41 (0.57–3.51)	0.46	
<i>BRAF</i>				
WT	98	Ref		
Non-V600E	6	0.81 (0.17–4.43)	0.8	
V600E	6	0.23 (0.05–1.06)	0.059	
<i>Nevi count</i>				
<20	207	3.92 (2.09–7.43)	<0.001	
≥20	42	Ref		

OR, odd ratio; Ref, reference; WT, wild type.




**Fig. 4.** Partial least squares regression score plot with the introduction of cumulative sun damage status. CSD, cumulative sun damage.

Although mutations of *pTERT* are usually associated with high-CSD, they are also present in low-CSD melanomas.<sup>10–12</sup> Indeed, they are evenly distributed across SE grades of CMs,<sup>9</sup> which is why we did not observe a statistically significant association between *pTERT* mutations and the grade of SE in NACLMs. However, as per *BRAF*, also *pTERT* mutations were more prevalent in grade II and III vs grade I SE (Table 2).

Mutations in *c-KIT* were rare and not related to SE grade, as previously observed for CMs,<sup>9</sup> which was also observed when using the low- and high-CSD classification.<sup>13</sup>

Clinical and pathological variables further supported these results. Head and neck location, female gender, older age, and presence of lentiginos in the area where the NACLM appeared were associated with



**Fig. 5.** Partial least squares discriminant analysis weights by cumulative sun damage status. CSD, cumulative sun damage; location 1, head/neck; 2, upper extremity; 3, trunk; 4, lower extremity.

**Table 4**

Univariate ordinal logistic regressions quantifying partial least squares regression results with solar elastosis grade as the response variable in the restricted dataset of 110 patients with data of *BRAF* and *NRAS* status. Location 1, head/neck; 2, upper extremity; 3, trunk; 4, lower extremity.

Univariate analysis		Elastosis grade	
Ordinal logistic regression	#	OR (95%CI)	p
<i>Location</i>			
1	89	Ref	
2	7	0.08 (0.02–0.35)	0.001
3	10	0.04 (0.009–0.16)	<0.001
4	4	0.04 (0.005–0.3)	0.002
<i>Age</i>			
		1.06 (1.03–1.1)	<0.001
<i>Gender</i>			
Female	46	1.81 (0.87–3.84)	0.11
Male	64	Ref	
<i>Presence of lentiginos in melanoma area</i>			
No	15	Ref	
Yes	95	3.85 (1.41–10.87)	0.009
<i>Regression</i>			
No	94	7.01 (2.52–20.66)	<0.001
Yes	16	Ref	
<i>BRAF</i>			
WT	98	Ref	
Non-V600E	6	0.81 (0.17–4.43)	0.79
V600E	6	0.23 (0.05–1.06)	0.059
<i>Nevi count</i>			
<20	89	4.06 (1.64–10.36)	0.003
≥20	21	Ref	

OR, odd ratio; Ref, reference; WT, wild type.




Fig. 6. Partial least squares regression weights by solar elastosis grade in the restricted dataset of 110 patients with data of *BRAF* and *NRAS* status. CSE, history of chronic solar exposure; location 1, head/neck; 2, upper extremity; 3, trunk; 4, lower extremity.

a higher SE grade, whereas having 20 or more nevi or showing regression in the histological slides was associated with a lower SE grade. These findings are consistent with previously published literature on CM and SE.<sup>9,14</sup> Remarkably, they showed a spectrum-like distribution of CM clinical characteristics across SE grades (as opposed to a clustered distribution). For example, mild SE was more frequent in younger patient or in patients with a higher total nevus count, and progressively became less frequent with increasing age or lower total nevus count.<sup>14</sup> In our study, the clinical results were further endorsed by observing a correlated distribution of *BRAF* V600E mutation between SE grades, although it was not statistically significant. This association was demonstrated in a former study where the absence of elastosis was associated with younger age, benign nevus remnants, and positive *BRAF* V600E expression ( $p < 0.0001$ ), which is similar to our findings.<sup>9</sup>

These results indicate that LM/LMM should not be classified as a CM subtype based only on histology, but rather as a CM characterized by a lentiginous growth pattern and high CSD in the adjacent dermis. This would tend to endorse the new WHO classification of low-CSD and high-CSD melanomas instead of SSMS and LMMs.

The strengths of the study are the prospectively built database and the statistical methodology applied.

The main limitation of the study is the low prevalence of mutations of *BRAF* and of the other genes analyzed.

### Conclusions

The results of the present study showed that SE grade is helpful to classify NACLMS across different groups distinguished by their clinical,

pathological, and molecular features. This points out the importance of reporting the grade of SE in the pathological report. Indeed, SE grade seemed to classify NACLMS more precisely than CSD. Although the results endorse the new WHO classification of low- and high-CSD melanomas, they also hint that these two categories are opposite poles of the same disease spectrum that varies by the grade of SE. Further studies with more molecular and genetic data are needed to confirm or refute these results.

### Conflict of interest

Eduardo Nagore is a member of the [Editorial Board, E-i-C] of Actas Dermo-Sifiliográficas and declares that he has not participated in or had access to information regarding the review and acceptance process of the manuscript. The other authors declare that they have no conflicts of interest.

### Appendix A. Supplementary data

Supplementary data associated with this article can be found in the online version available at <https://doi.org/10.1016/j.end-inu.2024.06.004>.

### References

1. Elder DE, Barnhill RL, Bastian BC, et al. Melanocytic tumour classification and the pathway concept of melanoma pathogenesis. In: Elder DE, Massi D, Scolyer RA, Willemze R, eds. *Classification of Skin Tumours*. Lyon, France: IARC; 2018:66–71.

2. Elder DE, Bastian BC, Cree IA, Massi D, Scolyer RA. The 2018 world health organization classification of cutaneous, mucosal, and uveal melanoma: detailed analysis of 9 distinct subtypes defined by their evolutionary pathway. *Arch Pathol Lab Med.* 2020;1444:500–522.
3. Elder DE, Bastian BC, Kim J, et al. Lentigo maligna melanoma. In: Elder DE, Massi D, Scolyer RA, Willemze R, eds. *Classification of Skin Tumours*. Lyon, France: IARC; 2018:102–104.
4. Massi G, LeBoit PE. Lentigo maligna. In: Massi G, LeBoit PE, eds. *Histological Diagnosis of Nevi and Melanoma*. Heidelberg, Germany: Springer; 2014:437–444.
5. King R. Lentiginous melanoma. *Arch Pathol Lab Med.* 2011;1353:337–341.
6. Duncan LM, Bastian BC, Elder DE, Mihm MC Jr. Low-CSD melanoma (superficial spreading melanoma). In: Elder DE, Massi D, Scolyer RA, Willemze R, eds. *Classification of Skin Tumours*. Lyon, France: IARC; 2018:76–77.
7. Landi MT, Bauer J, Pfeiffer RM, et al. Mcl1 germline variants confer risk for braf-mutant melanoma. *Science.* 2006;3135786:521–522.
8. Viros A, Fridlyand J, Bauer J, et al. Improving melanoma classification by integrating genetic and morphologic features. *PLoS Med.* 2008;5:e120.
9. Lade-Keller J, Yuusufi S, Riber-Hansen R, Steiniche T, Stougaard M. Telomerase reverse transcriptase promoter mutations and solar elastosis in cutaneous melanoma. *Melanoma Res.* 2018;28:398–409.
10. Motaparthy K, Kim J, Andea AA, et al. Tert and tert promoter in melanocytic neoplasms: current concepts in pathogenesis, diagnosis, and prognosis. *J Cutan Pathol.* 2020;47:710–719.
11. Millan-Esteban D, Pena-Chilet M, Garcia-Casado Z, et al. Mutational characterization of cutaneous melanoma supports divergent pathways model for melanoma development. *Cancers (Basel).* 2021;13:20.
12. Manrique-Silva E, Rachakonda S, Millan-Esteban D, et al. Clinical, environmental and histological distribution of braf, nras and tert promoter mutations among patients with cutaneous melanoma: a retrospective study of 563 patients. *Br J Dermatol.* 2021;1843:504–513.
13. Millan-Esteban D, Garcia-Casado Z, Manrique-Silva E, et al. Distribution and clinical role of kit gene mutations in melanoma according to subtype: a study of 492 Spanish patients. *Eur J Dermatol.* 2021;31:830–838.
14. Kvaskoff M, Pandeya N, Green AC, et al. Solar elastosis and cutaneous melanoma: a site-specific analysis. *Int J Cancer.* 2015;13612:2900–2911.